Summary

Other Scenarios:

Buyer: Cambrex Corporation (CBM) Last Price: 12.13 Market Cap.: 343.05M
Target: Penwest Pharmaceuticals (PPCO) Last Price: 12.52 Market Cap.: 291.57M

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 875
Biopharmaceuticals   336
Medical Devices   246
Outsourced Services 65
Scientific Products   39

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 31)
  • Pharmaceutical Manufacturing Services
  • BioAssay Services
Target (Total: 12)
  • SyncroDose
  • Geminex
  • TIMERx
  • Gastroretentive Drug Delivery System
Buyer
  • OsteoAssay Human Bone Plate Bone Resorption Assay
  • OsteoLyse Collagen Bone Resorption Assay
  • CalciFlour Flourescent Calcium Assay
  • OrCel (Bilayered Cellular Matrix)
Target
  • Procardia XL (Nifedipine)
  • PW2132 (Torsemide ER)
  • PW4110
  • PW4153

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 2)
  • Geron Corporation (GERN)
  • Logility, Inc. (LGTY)
Target (Total: 2)
  • Mylan Laboratories Inc. (MYL)
  • DRAXIS Health Inc. (USA) (DRAX)
Buyer (Total: 9)
  • Alpharma Inc. (ALO)
  • Geron Corporation (GERN)
  • Tercica, Inc. (TRCA)
  • Aastrom Biosciences, Inc. (ASTM)
Target (Total: 4)
  • Mylan Laboratories Inc. (MYL)
  • sanofi-aventis (ADR) (SNY)
  • Endo Pharmaceuticals (ENDP)
  • Merck KGaA

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 1,916 75
Revenue Per Employee 262,136.9 42,215.6
Total Revenue 125.5 0.8
Total Expenses 117.7 8.2
Other Revenue 1.7 0.0
Cost of Revenue 78.5 0.1
SG&A Expense 33.9 3.7
Research & Development 5.3 4.4
Other Operating Expense 0.0 0.0
Operating Income 7.8 -7.4
Unusual Income 0.0 0.0
LT Debt to Capital 39.7 n/a
Fwd P/E 22.93 -7.88
Fwd P/Rev n/a 78.52
Book Value 246.6 n/a
Curr Portion of LTD/Cap Lease 0.0 n/a

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Outsourced Services > Development/Manufacturing Services > Contract Manufacturing Organizations (CMO) > Pharmaceuticals > Active/Intermediate Chemicals

Target

Focused (): *Healthcare > Outsourced Services > Drug Delivery Technology > Oral Delivery

Business Description

Buyer

Cambrex Corporation (Cambrex) is a life sciences company focused on providing products and services that accelerate and improve the discovery and commercialization of human therapeutics. The Company primarily supplies its products and services worldwide to pharmaceutical and biopharmaceutical companies, generic drug companies, biotechnology companies and research organizations. Cambrex operates in three segments: Bioproducts, Biopharma and Human Health. On February 2, 2006, the Company acquired Cutanogen Corporation. On October 19, 2006, the Company signed a definitive stock purchase agreement to sell two businesses within the Human Health segment to a holding company controlled by International Chemical Investors II S.A. The sale was completed on October 27, 2006. On October 23, 2006, Cambrex entered into a stock purchase agreement with Lonza Group AG for the sale of the businesses that comprise the Bioproducts and Biopharma segments. This sale was completed on February 6, 2007.

Target

Penwest Pharmaceuticals Co. (Penwest) develops pharmaceutical products based on drug delivery technologies with a focus on products that address disorders of the nervous system. In June 2006, the United States Food and Drug Administration (FDA), approved for marketing Opana ER, an extended release formulation of oxymorphone hydrochloride that the Company developed with Endo Pharmaceuticals Inc (Endo), using its TIMERx drug delivery technology. Penwest is also developing product candidates designed for the treatment of pain, epilepsy, Parkinson?s disease and spasticity, as well as a product candidate for the treatment of edema resulting from congestive heart failure. The Company conducts its business primarily in North America.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 37.62 90.55
Operating Margin % 7.21 -1,012.23
Quick Ratio 1.01 n/a
Current Ratio 2.1 n/a
Coverage Ratio -0.42 -0.06
Total Assets 606.4 n/a
Return on Equity % -0.5 n/a
Return on Assets % -0.21 n/a
Cash+ ST Inv. Per Share 1.24 n/a
Total Debt 162.4 0.0
Total Debt to Equity % 65.83 n/a
Total Debt to Tangible Equity % 164.95 n/a
Debt to Asset % 26.78 n/a

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Medical Devices  
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
  
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
  
Outsourced Services
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
  
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
  
Scientific Products  
Bioanalytical Instruments
The Bioanalytical Instruments Subsector includes scientific products, devices and apparatuses that determine the quantitative and qualitative nature of a biological samples.
  
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals  
Cardiovascular System  
Heart Disorders  
Angina  
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.

Target Products:

  • Procardia XL (Nifedipine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • PW2132 (Torsemide ER)
  
Vascular Disorders  
Hypertension  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Target Products:

  • Procardia XL (Nifedipine)
  
Neurology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Target Products:

  • PW4110
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Target Products:

  • PW4153
  • PW4150
  • PW4158
  
Pain Management  
Narcotics  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Target Products:

  • Opana ER (Oxymorphone Hydrochloride Extended Release)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Target Products:

  • PW4142 (Nalbuphine ER)
  
Medical Devices  
Clinical Diagnostics  
Immunoassays  
Reagents  
Test Kits  
Special/Immuno Chemistry  
Growth/Bone  
Collagens
Immunoassay test kits which quantitatively measures derivatives of collagen in plasma or serum.

Buyer Products:

  • OsteoAssay Human Bone Plate Bone Resorption Assay
  • OsteoLyse Collagen Bone Resorption Assay
  • CalciFlour Flourescent Calcium Assay
  
Plastic/Reconstructive Surgery  
Surgical  
Procedure/Region Specific  
Skin Grafts  
Artificial Skin  
Cellular
Skin grafts that contain living human cells.

Buyer Products:

  • OrCel (Bilayered Cellular Matrix)
  
Outsourced Services
Development/Manufacturing Services  
Contract Manufacturing Organizations (CMO)  
Pharmaceuticals  
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.

Buyer Products:

  • Pharmaceutical Manufacturing Services
  
Packaging Services
Outsourced companies that provide packaging services for healthcare products.

Buyer Products:

  • Pharmaceutical Manufacturing Services
  
Drug Delivery Technology  
Oral Delivery  
Hydrogel Based/Polymer Coated
Drug Delivery Technologies used to deliver drugs in a jelly like base which are enclosed using a polymer matrix.

Target Products:

  • SyncroDose
  • Geminex
  • TIMERx
  
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.

Target Products:

  • Gastroretentive Drug Delivery System
  
Drug Discovery Services  
Lead Discovery/Validation/Optimization  
Assay Development
Bioanalytical services that are used to develop biologically based tests for use in high throughput screening (HTS).

Buyer Products:

  • BioAssay Services
  
Scientific Products  
Bioanalytical Instruments  
Biomolecular  
Electrophoresis  
Gel Electrophoresis (GE)  
Accessories
Supplementary products used to enhance the performance of a gel electrophoresis (GE) system.

Buyer Products:

  • Cambrex Bioproducts
  
Components  
Gel Cassettes
Gel electrophoresis (GE) components that include a cartridge filled with a gelatin material used for the separation of protein samples.

Buyer Products:

  • Cambrex Bioproducts
  
Systems  
Horizontal/Vertical  
Nucleic Acid
Horizontal or vertical gel electrophoresis (GE) systems used to analyze DNA/RNA samples.

Buyer Products:

  • FlashGel DNA/RNA Systems
  
Consumables  
Bioanalytical Chemistry  
Cell Biology  
Apoptosis  
Kits
A collection of reagents, standards, and other consumables assembled for used in apoptosis analyses.

Buyer Products:

  • ApoGlow
  
Reagents
Chemicals used in the preparation and analysis of samples during apoptosis analyses.

Buyer Products:

  • Cell Analysis Reagents
  
Cell Culture  
Cell Lines
Cell biology consumables that is a permanently established cell culture which proliferates indefinitely given appropriate fresh medium and space.

Buyer Products:

  • Human Corneal Epithelial Model
  • Clonetics Primary Cell and Media Systems
  • Renal Epithelial Cell Model
  • Poietics- Human Differentiating Cell Systems
  
Media
Cell biology consumables used for the growth of cells or organs.

Buyer Products:

  • Poietics- Human Differentiating Cell Systems
  • Classical/Speciality Media
  • Cambrex Bioproducts
  
Reagents  
Antibiotics
Cell culture reagents that are used during cellular assays.

Buyer Products:

  • Cambrex Bioproducts
  
Growth Factors
Cell culture reagents that are used during cellular assays.

Buyer Products:

  • Cambrex Bioproducts
  
Stains/Dyes
Cell culture reagents used for the coloration of samples.

Buyer Products:

  • Cell Analysis Reagents
  
Transfection
Cell culture reagents that are used to introduce DNA into a recipient eukaryote cell and its subsequent integration into the recipient cells chromosomal DNA

Buyer Products:

  • Cambrex Bioproducts
  
Sera  
Animal Sera
Sera obtained from animals.

Buyer Products:

  • Cambrex Bioproducts
  
Human Sera
Sera obtained from humans.

Buyer Products:

  • Cambrex Bioproducts
  
Cell Proliferation  
Kits
Cell proliferation consumables that are a collection of reagents, standards, and other consumables assembled for used in various biological analyses.

Buyer Products:

  • ViaLight Series
  
Cytotoxicity  
Kits
Consumables used in cytotoxicity analysis, which indicates destruction of target cells by measuring chemicals released by damaged cells.

Buyer Products:

  • ToxiLight
  • Cell Analysis Reagents
  • ViaLight Series
  
Signal Transduction  
Kits
A collection of reagents, standards, and other consumables assembled for used in signal transduction analyses.

Buyer Products:

  • PKLight- HTS Protein Kinase Assay Kit
  
Reagents
Chemicals used in the preparation and analysis of samples during signal transduction analyses.

Buyer Products:

  • G-Protein Coupled Receptors
  
Microbiology  
Identification/Detection  
Kits
A collection of reagents, standards, and other consumables assembled for used in various biological analyses.

Buyer Products:

  • MycoAlert Mycoplasma Detection Assay
  
Reagents
Microbial analysis reagents used for the detection of bateriocide endotoxins.

Buyer Products:

  • Cambrex Bioproducts
  
Stains/Dyes
Microbiological reagents used for the coloration of samples.

Buyer Products:

  • Cambrex Bioproducts
  • SYPRO
  • SYBR Green I
  
Molecular Biology  
Electrophoresis  
Gel Electrophoresis (GE)  
Gels
Gel electrophoresis consumable used for the separation of biological samples, including acrylamides, bisacrylamides, acrylamides/bisacrylamides, and agarose.

Buyer Products:

  • GelBond Series
  • Electrophoresis Gels
  
Reagents  
Buffers
Gel electrophoresis consumables that have a fixed concentration used to transfer the electrical current through.

Buyer Products:

  • AccuGENE
  
Stains/Dyes
Gel electrophoresis substances used for the coloration of samples.

Buyer Products:

  • SYPRO
  • SYBR Green I
  • GelStar
  • ProSieve- Protein Markers
  
Standards
Gel electrophoresis chemicals used as a reference compound.

Buyer Products:

  • Megabase DNA
  
Microplate Readers  
Kits
Molecular biology consumable kits used with microplate readers

Buyer Products:

  • ReportaLight Plus
  
Nucleic Acid Analysis  
Kits  
Nucleic Acid  
Transfection
Nucleic acid analysis kits that are used for the introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cells chromosomal DNA

Buyer Products:

  • Cambrex Bioproducts
  
Protein Analysis  
Kits  
Detection
Protein analysis kits used for the detection of amino acids.

Buyer Products:

  • PDELight HTS Phosphodiesterase Assay
  
Purification
Protein analysis kits used for the purification of amino acids.

Buyer Products:

  • Versalinx Chemical Affinity tools
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Target
  Johnson & Johnson n/a 180,269.466 17.47 15.51 3.26 3.00 15.42
Elan Corporation, plc (ADR) n/a 7,007.945 n/a -26.77 11.64 8.63 n/a
King Pharmaceuticals, Inc. n/a 4,965.024 14.02 12.78 2.46 2.50 4.24
Biovail Corporation (USA) n/a 3,968.336 19.46 13.97 3.71 4.71 8.15
K-V Pharmaceutical Company n/a 1,256.573 26.43 n/a 3.30 n/a 5.07
Alpharma Inc. n/a 985.464 16.13 17.43 1.49 1.41 2.13
Ligand Pharmaceuticals Inc. n/a 694.026 n/a -34.40 4.92 25.42 n/a
SkyePharma PLC (ADR) n/a 387.935 n/a -15.44 3.87 3.18 n/a
SCOLR Pharma Inc. n/a 97.403 n/a n/a 42.75 n/a 5.74
BioDelivery Sciences International, Inc. n/a 77.667 n/a -15.87 27.98 6.26 n/a
Elite Pharmaceuticals, Inc. n/a 46.797 n/a -8.04 67.64 n/a 7.20
Purdue Pharma L.P. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Geron Corporation n/a 534.882 n/a -16.42 148.11 45.05 2.45
Logility, Inc. n/a 122.967 22.00 23.02 3.00 3.02 4.94
Target
  Mylan Laboratories Inc. n/a 4,940.952 14.27 13.89 3.41 3.13 5.45
DRAXIS Health Inc. (USA) n/a 228.330 19.77 20.88 2.57 2.46 2.50

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Alpharma Inc. n/a 985.464 16.13 17.43 1.49 1.41 2.13
Geron Corporation n/a 534.882 n/a -16.42 148.11 45.05 2.45
Tercica, Inc. n/a 316.024 n/a -4.32 209.70 20.13 3.51
Aastrom Biosciences, Inc. n/a 173.759 n/a n/a 210.69 n/a 4.84
Cyclacel Pharmaceuticals Inc. n/a 157.139 n/a -4.72 405.84 101.84 3.07
CEL-SCI Corporation n/a 69.651 n/a -16.40 599.71 344.06 n/a
DOR BioPharma, Inc. n/a 19.514 n/a n/a 8.45 n/a n/a
Ortec International, Inc. n/a 7.171 n/a n/a n/a n/a n/a
Innovative Biosensors, Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  Mylan Laboratories Inc. 89.10% 4,940.952 14.27 13.89 3.41 3.13 5.45
sanofi-aventis (ADR) n/a 124,388.254 22.74 12.98 3.09 3.16 n/a
Endo Pharmaceuticals n/a 4,245.156 24.33 18.71 4.43 4.06 5.04
Merck KGaA n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  The Dow Chemical Company n/a 43,648.909 12.53 11.64 0.88 0.87 3.21
Crucell N.V. (ADR) n/a 1,462.433 n/a -75.19 14.05 4.89 3.76
Alpharma Inc. n/a 985.464 16.13 17.43 1.49 1.41 2.13
Geron Corporation n/a 534.882 n/a -16.42 148.11 45.05 2.45
Tercica, Inc. n/a 316.024 n/a -4.32 209.70 20.13 3.51
StemCells, Inc. n/a 198.137 n/a n/a 2,117.65 n/a 3.64
Aastrom Biosciences, Inc. n/a 173.759 n/a n/a 210.69 n/a 4.84
Cyclacel Pharmaceuticals Inc. n/a 157.139 n/a -4.72 405.84 101.84 3.07
Cytori Therapeutics Inc. (USA) n/a 129.349 n/a n/a 16.32 n/a n/a
CEL-SCI Corporation n/a 69.651 n/a -16.40 599.71 344.06 n/a
DOR BioPharma, Inc. n/a 19.514 n/a n/a 8.45 n/a n/a
Ortec International, Inc. n/a 7.171 n/a n/a n/a n/a n/a
GlycoGenesys, Inc. n/a 0.352 n/a n/a n/a n/a 0.67
Chugai Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  sanofi-aventis (ADR) n/a 124,388.254 22.74 12.98 3.09 3.16 n/a
Mylan Laboratories Inc. n/a 4,940.952 14.27 13.89 3.41 3.13 5.45
Endo Pharmaceuticals n/a 4,245.156 24.33 18.71 4.43 4.06 5.04
DRAXIS Health Inc. (USA) n/a 228.330 19.77 20.88 2.57 2.46 2.50
Pharmaceutics International, Inc. n/a n/a n/a n/a n/a n/a n/a
Merck KGaA n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 450.3 3.4 453.7
Other Revenue 5.2 0.0 5.2
Total Revenue 455.5 3.4 458.8
Cost of Revenue 284.1 0.3 284.4
SG&A Expense 117.3 14.3 131.6
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 21.2 22.9 44.1
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Total Expenses 422.6 37.5 460.2
Operating Income 32.8 -34.2 -1.3
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -13.9 2.2 -11.7
Other, Net -1.5 0.0 -1.5
Income Before Taxes 17.5 -32.0 -14.5
Income Taxes 18.7 0.0 18.7
Income After Taxes -1.2 -32.0 -33.2
Net Income - Excl. Xord. Items -1.2 -32.0 -33.2
Discontinued Operations -28.6 0.0 -28.6
Accounting Change -0.2 0.0 -0.2
Net Income - Incl. Xord. Items -30.1 -32.0 -62.1
Income Avail. to Common -30.1 -32.0 -62.1
Share Items
Basic Avg. Shares Outstanding 27.1 23.1 50.2
Basic EPS - Excl. Xord. Items n/a n/a -0.66
Basic EPS - Incl. Xord. Items n/a n/a -1.24
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 27.3 23.1 50.4
F.D. EPS - Excl. Xord. Items n/a n/a -0.66
F.D. EPS - Incl. Xord. Items n/a n/a -1.23
Dividends Per Common Share 0.12 0.00 0.12
Balance Sheet
Assets
Cash and Equivalents 33.7 n/a 33.7
Accounts Receivable 74.0 n/a 74.0
Inventory 94.6 n/a 94.6
Prepayments and Advances 22.4 n/a 22.4
Other Current Assets 0.0 n/a 0.0
Current Assets 224.8 n/a 224.8
Accum D&A 0.0 n/a 0.0
PPE, Net 227.0 n/a 227.0
Goodwill & Intangibles 148.2 n/a 148.2
Other Assets 0.0 n/a 0.0
Other LT Assets 6.4 n/a 6.4
Total Assets 606.4 n/a 606.4
Liabilities
Accounts Payable 42.2 n/a 42.2
Payable/Accrued 0.0 n/a 0.0
Accrued Expenses 64.9 n/a 64.9
ST Debt 0.0 n/a 0.0
Other (Current) Liabilities 0.0 n/a 0.0
Current Liab. 107.1 n/a 107.1
LT Debt 162.4 n/a 162.4
Total LT Debt 162.4 n/a 162.4
Deferred Taxes 30.2 n/a 30.2
Other LT Liab. 60.0 n/a 60.0
Total Liabilities 359.7 n/a 359.7
Shareholders Equity
Common Stock 3.0 n/a 3.0
Additional Paid in Capital 241.4 n/a 241.4
Retained Earnings 28.9 n/a 28.9
Treasure Stock -20.8 n/a -20.8
Other Equity -5.8 n/a -5.8
Total Equity 246.6 n/a 246.6
Total Liab. & Equity 606.4 n/a 606.4
Shares Outstanding 27.7 n/a 27.7
Cash Flow
Operating Cash Flow
CF Net Income -29.7 n/a -29.7
CF Depreciation 14.1 n/a 14.1
CF Deferred Taxes 2.1 n/a 2.1
Other Non-Cash Items 37.6 n/a 37.6
Change in Working Capital 6.7 n/a 6.7
Total Cash From Operating Activities 30.7 n/a 30.7
Investing Cash Flow (not calculated)
Capital Expenditures -20.6 n/a -20.6
Other Investing Cash Flows -1.6 n/a -1.6
Total Cash From Investing Activities -22.2 n/a -22.2
Financing Cash Flow (not calculated)
Dividends Paid -1.6 n/a -1.6
Purchase Or Sale of Stock 20.0 n/a 20.0
Purchase and Retirement of Debt -24.2 n/a -24.2
Other Financing Cash Flow 0.0 n/a 0.0
Total Cash From Financing Activities -5.8 n/a -5.8
Exchange Rate Effects 1.3 n/a 1.3
Net Change in Cash 4.1 n/a 4.1
Cash Taxes Paid 16.7 n/a 16.7
Cash Interest Paid 13.6 n/a 13.6